Eledon Pharmaceuticals, Inc.
DE ˙ DB ˙ US28617K1016
2,92 € ↓ -0,04 (-1,35%)
2026-06-04
AKTIENPREIS
SecurityDE:2TK / Eledon Pharmaceuticals, Inc.
InstitutionKingdon Capital Management, L.l.c.
Latest Disclosed Ownership1,039,275 shares
Latest Disclosed Value $ 3,200,967
Kingdon Capital Management, L.l.c. ownership in 2TK / Eledon Pharmaceuticals, Inc.

On May 15, 2026 - Kingdon Capital Management, L.l.c. filed a 13F-HR form disclosing ownership of 1,039,275 shares of Eledon Pharmaceuticals, Inc. (DE:2TK) valued at $2,390,332 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 1,039,275 shares of Eledon Pharmaceuticals, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $3,034,683 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ELEDON PHARMACEUTICALS COM 28617K101 1,039,275 0 0.00 3,201 103.95 0.3514
2026-02-17 2025-12-31 13F ELEDON PHARMACEUTICALS COM 28617K101 1,039,275 1,039,275 1,569 0.1866
2016-05-16 2016-03-31 13F TOKAI PHARMACEUTICALS COM 88907J107 0 -87,983 -100.00 0 -100.00
2016-02-16 2015-12-31 13F TOKAI PHARMACEUTICALS COM 88907J107 87,983 -570,419 -86.64 767 -88.74 0.0373
2015-11-16 2015-09-30 13F TOKAI PHARMACEUTICALS COM 88907J107 658,402 -82,576 -11.14 6,814 -30.86 0.3285
2015-08-14 2015-06-30 13F TOKAI PHARMACEUTICALS COM 88907J107 740,978 63,000 9.29 9,855 28.64 0.3853
2015-05-15 2015-03-31 13F TOKAI PHARMACEUTICALS COM 88907J107 677,978 110,000 19.37 7,661 -8.49 0.3250
2015-02-17 2014-12-31 13F TOKAI PHARMACEUTICALS COM 88907J107 567,978 362,978 177.06 8,372 169.89 0.3677
2014-11-14 2014-09-30 13F TOKAI PHARMACEUTICALS COM 88907J107 205,000 205,000 3,102 0.1394
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.